Precision Medicine   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Bethesda MD United States (2012)

Organization Overview

First Clinical Trial
2016
NCT02963493
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Innovative Precision Medicine Group (IPM), Hangzhou, China. | Precision for Medicine | Precision For Medicine | Precision Oncology | Precision Oncology LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 3)

Coronary Disease (Phase 1)

Familial Primary Pulmonary Hypertension (Phase 2)

Hypertension (Phase 2)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Neoplasms, Second Primary (Phase 3)

Pneumonia (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 14